ADC Therapeutics (ADCT) Deferred Taxes (2023)

ADC Therapeutics' (ADCT) quarterly Deferred Taxes came in at $42.9 million in Q4 2023, up 7514.19% quarter-over-quarter from -$578000.0 in Q3 2023.

ADC Therapeutics (ADCT) Deferred Taxes (2023) Analysis & Trends

ADC Therapeutics has disclosed Deferred Taxes across 1 years of filings, most recently posting $42.9 million for Q4 2023.

Deferred Taxes for Q4 2023 came in at $42.9 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2024 was $42.9 million (changed N/A YoY), and the FY2023 annual result was $37.1 million, up 2388.96% from the prior year.
Deferred Taxes came in at $42.9 million for Q4 2023 at ADC Therapeutics, up from -$578000.0 in the prior quarter.
In the past five years, Deferred Taxes ranged from a high of $42.9 million in Q4 2023 to a low of -$5.1 million in Q2 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Deferred Taxes (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn	-
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-	-859,000.00
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn	-65.30 Mn
9	Abivax	91.71 Bn	91.71 Bn	-	-
10	ADC Therapeutics	167.24 Mn	-63.76 Mn	7.33 Mn	-

Download Data